View Item 

Show simple item record

Trimethoprim‐Sulfamethoxazole Activity and Pharmacodynamics against Glycopeptide‐Intermediate Staphylococcus aureus

dc.contributor.authorClose, Sandy J.en_US
dc.contributor.authorMcBurney, Christopher R.en_US
dc.contributor.authorGarvin, Cory G.en_US
dc.contributor.authorChen, David C.en_US
dc.contributor.authorMartin, Steven J.en_US
dc.date.accessioned2012-03-16T16:01:30Z
dc.date.available2012-03-16T16:01:30Z
dc.date.issued2002-08en_US
dc.identifier.citationClose, Sandy J.; McBurney, Christopher R.; Garvin, Cory G.; Chen, David C.; Martin, Steven J. (2002). "Trimethoprim‐Sulfamethoxazole Activity and Pharmacodynamics against Glycopeptide‐Intermediate Staphylococcus aureus ." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 22(8). <http://hdl.handle.net/2027.42/90392>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90392
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.titleTrimethoprim‐Sulfamethoxazole Activity and Pharmacodynamics against Glycopeptide‐Intermediate Staphylococcus aureusen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumSchool of Public Health, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherSchool of Pharmacy, University of Missouri at Kansas City, Kansas City, Missourien_US
dc.contributor.affiliationotherInfectious Disease Research Laboratory, College of Pharmacy, University of Toledo, Toledo, Ohioen_US
dc.identifier.pmid12173801en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90392/1/phco.22.12.983.33599.pdf
dc.identifier.doi10.1592/phco.22.12.983.33599en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceHershberger E., Aeschlimann J.R., Moldovan T., Rybak M.J.. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin‐sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin‐intermediate Staphylococcus aureus by time‐kill curve methods. Antimicrob Agents Chemother 1999; 13: 717 – 21.en_US
dc.identifier.citedreferenceKim M., Pai C.H., Woo J.H., Ryu J.S., Hiramatsu K.. Vancomycin‐intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000; 38: 3879 – 81.en_US
dc.identifier.citedreferenceEllison R.T., Judson F.N., Peterson L.C., Cohn D.L., Ehret J.M.. Oral rifampin and trimethoprim‐sulfamethoxazole therapy in asymptomatic carriers of methicillin‐resistant Staphylococcus aureus infections. West J Med 1984; 140: 735 – 40.en_US
dc.identifier.citedreferenceTenover F.C., Lancaster M.V., Hill B.C., et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020 – 7.en_US
dc.identifier.citedreferenceMoreira B., Boyle‐Vavra S., deJonge B.L.M., Baum R.S.. Increased production of penicillin‐binding protein 2, increased detection of other penicillin‐binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 1788 – 93.en_US
dc.identifier.citedreferenceCui L., Murakami H., Kuwahara‐Arai K., Hanaki H., Hiramatsu K.. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000; 44: 2276 – 85.en_US
dc.identifier.citedreferenceSieradzki K., Tomasz A.. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin‐resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179: 2557 – 66.en_US
dc.identifier.citedreferenceBoyle‐Vavra S., Berke S.K., Lee J.C., Daum R.S.. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2000; 44: 272 – 7.en_US
dc.identifier.citedreferenceWilliams D., Bergan T., Moosdeen F.. Arrival of vancomycin resistance in Staphylococcus aureus. Antibiotic Chemotherapy; Newsletter of the International Society of Chemotherapy 1997; 1 ( 2 ): 1.en_US
dc.identifier.citedreferenceRybak M.J., Hershberger E., Moldovan T., Grucz R.. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin‐dalfopristin against staphylococci and enterococci, including vancomycin‐intermediate and ‐resistant strains. Antimicrob Agents Chemother 2000; 44: 1062 – 6.en_US
dc.identifier.citedreferenceElwell L.P., Wilson H.R., Knick V.B., Keith B.R.. In vitro and in vivo efficacy of the combination trimethoprim‐sulfamethoxazole against clinical isolates of methicillin‐resistant Staphylococcus aureus. Antimicrob Agents Chemother 1986; 29: 1092 – 4.en_US
dc.identifier.citedreferenceYeldandi V., Strodtman R., Lentino J.R.. In‐vitro and in‐vivo studies of trimethoprim‐sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 1988; 22: 873 – 80.en_US
dc.identifier.citedreferenceTripodi M.F., Attanasio V., Adinolfi L.E., et al. Prevalence of antibiotic resistance among clinical isolates of methicillin‐resistant staphylococci. Eur J Clin Microbiol Infect Dis 1994; 13: 148 – 52.en_US
dc.identifier.citedreferenceScheel O., Lyon D.J., Rosdahl V.T., Adeyemi‐Doro A.B., Ling T.K., Cheng A.F.. In vitro susceptibility of isolates of methicillin‐resistant Staphylococcus aureus 1988–1993. J Antimicrob Chemother 1996; 37: 243 – 51.en_US
dc.identifier.citedreferenceSchmitz F.J., Verhoef J., Fluit A., Heinz H.P., Jones M.E.. Stability of the MICs of various antibiotics in different clonal populations of methicillin‐resistant Staphylococcus aureus. J Antimicrob Chemother 1998; 41: 311 – 15.en_US
dc.identifier.citedreferenceCohen M.A., Huband M.D.. Activity of clinafloxacin, trovafloxacin, quinupristin‐dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 1999; 33: 43 – 6.en_US
dc.identifier.citedreferenceMarkowitz N., Quinn E.L., Saravolatz L.D.. Trimethoprim‐sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390 – 8.en_US
dc.identifier.citedreferencePloy M.C., Grelaud C., Martin C., de Lumley L., Denis F.. First clinical isolate of vancomycin‐intermediate Staphylococcus aureus in a French hospital [letter]. Lancet 1998; 351: 1212.en_US
dc.identifier.citedreferenceHess M.A., Boucher B.A., Laizure S.C., et al. Trimethoprim‐sulfamethoxazole pharmacokinetics in trauma patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 1993; 13 ( 6 ): 602 – 6.en_US
dc.identifier.citedreferenceNational Committee for Clinical Laboratory Standards. Approved standard M7–A4. In: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Wayne, PA: NCCLS, 1997.en_US
dc.identifier.citedreferenceNational Committee for Clinical Laboratory Standards. Approved guidelines M26–A. In: Methods for determining bactericidal activity of antimicrobial agents. Wayne, PA: NCCLS, 1999.en_US
dc.identifier.citedreferenceHiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C.. Methicillin‐resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135 – 46.en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. Morb Mortal Wkly Rep MMWR 1997; 46: 765 – 6.en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. Morb Mortal Wkly Rep MMWR 1997; 46: 813 – 14.en_US
dc.identifier.citedreferenceSmith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493 – 501.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.22.12.983.33599.pdf
Size:
51.42KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.